Drug Profile
Research programme: Alzheimer's disease therapeutics - Eisai
Alternative Names: AD genetics programme - Eisai; Alzheimer's disease genetics programme - EisaiLatest Information Update: 25 May 2010
Price :
$50
*
At a glance
- Originator TorreyPines Therapeutics Inc
- Developer Eisai Co Ltd
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 10 Nov 2008 TorreyPines Therapeutics sells its Alzheimer's disease genetics programme to Eisai
- 22 Oct 2008 TorreyPines Therapeutics is actively seeking to sell/out-license this research programme (http://www.torreypinestherapeutics.com)
- 28 Sep 2007 Eisai and TorreyPines Therapeutics extend their existing genetics discovery collaboration in Alzheimer's disease for an additional year